slipped Tuesday after the company revealed that its marketing practices are being examined by the state of Connecticut.
Two months ago, Cephalon received subpoenas from the U.S. Attorney's office in Philadelphia asking for information about sales and promotional practices for the sleep disorders drug Provigil, the cancer pain reliever Actiq and Gabitril, an add-on treatment for epilepsy.
"We have had similar discussions" with the Connecticut attorney general's office, Cephalon said Tuesday in a quarterly financial report filed with the
Securities and Exchange Commission
. The company said it received "a voluntary request" from Connecticut seeking information about sales and promotional practices.
"We have agreed to comply with this voluntary request," Cephalon said. "These matters may involve the bringing of criminal charges and fines, and/or civil penalties." Cephalon said it couldn't predict the outcome of these matters.
Cephalon also said it was cooperating with Pennsylvania's attorney general, who is checking into media reports about "instances of abuse and diversion of Actiq."
Cephalon's stock closed down 35 cents, or 0.7%, to $49.42.